Effectiveness of rotavirus vaccine against hospitalized rotavirus diarrhea: A case–control study

Highlights • We evaluated RV-A vaccine effectiveness in a more ethnically diverse population. • We showed high VE despite the diversity of RV-A strains and prevalence of G2P4. • Protection lasted at least two years after the second dose vaccination. • The effect appeared to be higher against G1P8 an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-05, Vol.32 (23), p.2740-2747
Hauptverfasser:	Ichihara, Maria Y.T, Rodrigues, Laura C, Teles Santos, Carlos A.S, Teixeira, Maria da Gloria L.C, De Jesus, Sandra R, Alvim De Matos, Sheila M, Gagliardi Leite, Jose P, Barreto, Mauricio L
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute diarrhea hospitalization Allergy and Immunology Applied microbiology Biological and medical sciences Brazil - epidemiology Case studies Case-Control Studies Child diarrhea Child, Preschool Children & youth Diarrhea Diarrhea - epidemiology Diarrhea - prevention & control Diarrhea - virology Epidemiological Monitoring Female Fundamental and applied biological sciences. Psychology Genotypes Hospitalization Humans Immunization Immunization Schedule Infant Male Microbiology Miscellaneous Rotavirus Rotavirus - classification Rotavirus - genetics Rotavirus diarrhea Rotavirus Infections - epidemiology Rotavirus Infections - prevention & control Rotavirus Vaccines - administration & dosage Rotavirus Vaccines - therapeutic use Vaccine Vaccine effectiveness Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • We evaluated RV-A vaccine effectiveness in a more ethnically diverse population. • We showed high VE despite the diversity of RV-A strains and prevalence of G2P4. • Protection lasted at least two years after the second dose vaccination. • The effect appeared to be higher against G1P8 and G2P4 than against nonG1/G2.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.01.007